Global Information
회사소개 | 문의 | 비교리스트

기저세포암(기저세포상피종) : 파이프라인 리뷰

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 227551
페이지 정보 영문 403 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


기저세포암(기저세포상피종) : 파이프라인 리뷰 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 403 Pages

기저세포암이란 기저 세포로부터 발병하는 피부병의 일종입니다. 주요 증상에는 밀랍 모양의 혹, 흑갈색의 딱지, 흰 밀랍 모양의 반흔 등을 들 수 있습니다. 질병 소질에는 연령 및 가족력, 방사선 피폭, 면역 억제 요법 등이 있습니다. 주요 치료법에는 화학요법 및 외과 수술 등이 있습니다.

세계 각국에서의 기저세포암(기저세포상피종) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

서론

  • 조사 범위

기저세포암(기저세포상피종) - 개요

기저세포암(기저세포상피종) - 치료제 개발

  • 파이프라인 개요
  • 기업별 파이프라인 동향
  • 기업에서 개발중인 제품

기저세포암(기저세포상피종) - 치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

기저세포암(기저세포상피종) 치료제 개발에 참여하고 있는 기업

  • Biosceptre International Ltd
  • BLR Bio LLC
  • Cannabis Science Inc
  • Genextra Spa
  • Ignyta Inc
  • Laboratories Ojer Pharma SL
  • MediGene AG
  • Merck & Co Inc
  • Provectus Biopharmaceuticals Inc
  • Redx Pharma Plc
  • Regeneron Pharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Transgene SA

약제 개요

기저세포암(기저세포상피종) - 휴지중인 프로젝트

기저세포암(기저세포상피종) - 개발이 중지된 제품

기저세포암(기저세포상피종) - 제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

KSA 17.06.13

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Amgen Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bayer AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Galderma SA, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genentech Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Invion Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by IO Biotech ApS, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Leo Pharma AS, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Mayne Pharma Group Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Medivir AB, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by NuCana Plc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by PellePharm Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Phosplatin Therapeutics LLC, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by QBiotics Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Replimune Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Senhwa Biosciences Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Singh Biotechnology LLC, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2020, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 14, 8, 7 and 1 respectively.

Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Basal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q